FGFR1 and WT1 are markers of human prostate cancer progression.

Elizabeth Devilard, Franck Bladou, Olivier Ramuz, Gilles Karsenty, Jean-Philippe Dalès, Gwenaëlle Gravis, Catherine Nguyen, François Bertucci, Luc Xerri, Daniel Birnbaum

To cite this version:

Elizabeth Devilard, Franck Bladou, Olivier Ramuz, Gilles Karsenty, Jean-Philippe Dalès, et al.. FGFR1 and WT1 are markers of human prostate cancer progression.. BMC Cancer, 2006, 6, pp.272. 10.1186/1471-2407-6-272. inserm-00121110

HAL Id: inserm-00121110
https://inserm.hal.science/inserm-00121110
Submitted on 19 Dec 2006

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Research article

FGFR1 and WT1 are markers of human prostate cancer progression

Elizabeth Devilard*1, Franck Bladou2, Olivier Ramuz3, Gilles Karsenty2, Jean-Philippe Dalès4,5, Gwenaëlle Gravis6, Catherine Nguyen7, François Bertucci1,5,6, Luc Xerri1,3,5 and Daniel Birnbaum*1

Address: 1Centre de Recherche en Cancérologie de Marseille, Département d’Oncologie Moléculaire, UMR599 Inserm et Institut Paoli-Calmettes, Marseille, France, 2Département d’Urologie, Hôpital Salvador, Marseille, France, 3Département de Biopathologie, Institut Paoli-Calmettes, Marseille, France, 4Département de Pathologie, Hôpital Nord, Marseille, France, 5Faculté de Médecine, Université de la Méditerranée, Marseille, France, 6Département d’Oncologie Médicale, Institut Paoli-Calmettes, Marseille, France and 7Laboratoire TAGC, ERM206, Marseille-Luminy, France

Email: Elizabeth Devilard* - devilard@ciml.univ-mrs.fr; Franck Bladou - franck.bladou@mail.ap-hm.fr; Olivier Ramuz - oramuz@yahoo.fr; Gilles Karsenty - gilles.karsenty@mail.ap-hm.fr; Jean-Philippe Dalès - jpdales@mail.ap-hm.fr; Gwenaëlle Gravis - gravisg@marseille.fnclcc.fr; Catherine Nguyen - nguyen@tagc.univ-mrs.fr; François Bertucci - bertuccif@marseille.fnclcc.fr; Luc Xerri - xerril@marseille.fnclcc.fr; Daniel Birnbaum* - birnbaum@marseille.inserm.fr

* Corresponding authors

Abstract

Background: Androgen-independent prostate adenocarcinomas are responsible for about 6% of overall cancer deaths in men.

Methods: We used DNA microarrays to identify genes related to the transition between androgen-dependent and androgen-independent stages in the LuCaP 23.1 xenograft model of prostate adenocarcinoma. The expression of the proteins encoded by these genes was then assessed by immunohistochemistry on tissue microarrays (TMA) including human prostate carcinoma samples issued from 85 patients who had undergone radical prostatectomy.

Results: FGFR1, TACC1 and WT1 gene expression levels were associated with the androgen-independent stage in xenografts and human prostate carcinoma samples. MART1 protein expression was correlated with pT2 tumor stages.

Conclusion: Our results suggest that each of these four genes may play a role, or at least reflect a stage of prostate carcinoma growth/development/progression.

Background

Prostate adenocarcinoma is the most common cancer in men in western countries, and is responsible for about 6% of overall cancer deaths [1]. Localized prostate adenocarcinoma is usually treated by either surgery or radiotherapy. In the early stages, tumor growth is dependent on androgen stimulus and androgen ablation may be used as a complementary therapy. The tumor then progresses to an androgen-independent stage against which hormone therapy has no effect. Currently, there is no effective therapy against androgen-independent prostate cancer.
The molecular biology of prostate cancer is not well understood. Several previous reports have proposed candidate molecules linked to hereditary prostate cancer [3,4]. GSTP1, PTEN, TP53, and androgen receptor (AR) are mutated or deregulated in sporadic prostate cancer [5] and may become targets for innovative therapies. Recently, DNA microarrays experiments have identified other potential prognostic markers and/or targets, such as Hepsin/TMPRSS1, PSMA, and MMR genes [6,7] and gene fusions [8]. Overall, little is known about the progression from androgen-dependent to androgen-independent stages [2].

The LuCaP 23.1 human prostate carcinoma xenograft model [9] mimics the different stages of tumor growth and may be an adequate system to identify the molecular events associated with cancer progression [10]. Like for human samples, DNA microarray analyses of xenograft model systems have led to the discovery of several genes associated with cancer progression. However, although xenograft model systems are invaluable for gene discovery studies, as well as for experimental therapeutics, there is concern that growth of human cancer cells in an immunocompromised mouse host may not always be representative of progression of cancer in patients [11]. Combined gene and protein expression profilings – e.g. DNA microarrays and tissue microarrays (TMA) [12] – may allow easier or quicker validation of results provided by xenograft studies.

In the present work, we used DNA microarrays to identify candidate genes correlated with progression to androgen-resistant stage in the LuCaP 23.1 xenograft model. The expression of candidate genes with available and well-performing antibody was then assessed by immunohistochemistry (IHC) on TMA including human prostate carcinoma samples from 85 patients who had undergone radical prostatectomy.

**Methods**

**Patient samples**

Formalin-fixed, paraffin-embedded samples were obtained from 85 distinct prostatectomy specimens (Table 1). They included 80 tumor samples issued from prostatectomy specimens of carcinoma ranging from pT2aN0M0 to pT3bN0M0 stages (2002 pTNM classification of UICC), 5 carcinoma samples from carcinomas with distant metastases (N1 or M1 stages) classified as "hormone refractory" (HR), 11 benign prostate tissue samples, studied as control samples (these samples were obtained from benign tissue areas in 11 of the 85 above-mentioned prostatectomy specimens). This study was approved and executed in compliance with our institutional review board.

**LuCaP 23.1 xenograft model**

Fresh frozen tumor samples were obtained from four different mice bearing the LuCaP 23.1 xenograft [9]. Each mouse was sampled three times, reflecting three distinct stages of tumor progression: primary tumor (day 1 post-transplantation), hormone sensitive (HS) tumor (day 7 post-transplantation), and hormone refractory (HR) tumor (day 114 post-transplantation).

### Table 1: Patients and tumor characteristics.

| Characteristics | All patients (n = 85) |
|-----------------|----------------------|
| Median age (years) | 62                   |
| TNM classification: |                       |
| pT0 | 11                   |
| pT1 | 0                    |
| pT2a | 10                   |
| pT2b | 30                   |
| pT3a | 28                   |
| pT3b | 17                   |
| T3N1M1b | 3               |
| T3N1M1c | 2                |
| Gleason grading: |                       |
| 5 | 4                    |
| 6 | 8                    |
| 7 | 53                   |
| 8 | 15                   |
| 9 | 5                    |
| Median follow-up (months) | 60               |
| Metastatic relapse (n) | 4                 |
| Death (n) | 3                    |
RNA extraction

Total RNA was extracted from tissue samples by lysis in guanidium isothiocyanate and centrifugation over a cesium chloride cushion following standard protocols [13]. RNA quality was assessed by denaturing formaldehyde agarose gel electrophoresis and reverse-transcribed PCR (RT-PCR) amplification of the β2-microglobulin transcript.

DNA microarrays preparation and analysis

We used DNA microarrays to compare the mRNA expression profiles of ~1,000 selected genes between primary, HS, and HR tumors in the LuCaP 23.1 xenograft model of prostate carcinoma. RNA extracts were pooled according to the three distinct stages of tumor progression in the LuCaP 23.1 model (4 samples/tumor stage). DNA microarray hybridizations were done as previously described [14,15] on home-made nylon DNA microarrays (TAGC, Marseille-Luminy, France), which contained spotted PCR products from 945 human cDNA clones. Most genes were selected for a proven or putative implication in cancer and/or in immune reactions. Microarrays were hybridized with 33P-labeled probes made from 5 μg of total RNA. Probe preparations, hybridizations, and washes were done as previously described [14]. Briefly, 5 μg of total RNA were retrotranscribed in the presence of [-33P] dCTP (Amersham Biosciences). Hybridizations were done during 48 hours at 68°C in a final volume of 10 mL of buffer. After washes, arrays were exposed for 24 hours to phorimaging plates. Detection scanning was done with a FUJI BAS 5000 machine at 25-μm resolution (Raytest, Paris, France) and quantification of hybridization signals was done at room temperature as follows: after washes in phosphate buffer, followed by quenching of endogenous peroxidase activity by treatment with 0.1% H2O2, slides were first incubated with blocking serum (DAKO) for 1 hour. After washes, slides were incubated with biotinylated antibody against rabbit Ig for 20 min followed by streptavidin-conjugated peroxidase (DAKO LSABR2 kit). AEC was used as chromogen, according to the supplier’s recommendations for the DAKO LSAB2 kit (Dakocytomation, Glosturp, Denmark). The tissue sections were then counterstained with haematoxylin and coverslipped using Aquatex mounting solution (Merck, Darmstadt, Germany). IHC staining was assessed by two pathologists (OR, LX) and classified into two categories: negative versus positive IHC staining. Each IHC staining was obtained and analyzed twice.

Tissue microarray (TMA) construction

The TMA included 96 formalin-fixed, paraffin-embedded human prostate tissue samples. TMA was prepared as described [17] with slight modifications. For each tumor, one representative tumor area was carefully selected from a hematoxylin- and eosin-stained section of a donor block. Core cylinders with a diameter of 1,2 mm each were punched from each of these areas and deposited into a recipient paraffin block using a specific arraying device (Beecher Instruments, Silver Spring, MD). Five-μm sections of the resulting microarray block were made and used for IHC analysis after transfer to glass slides.

Immunohistochemical analysis

The antibodies used are listed in Table 2. PSA was used as a positive control of prostate tissue. Immunohistochemistry (IHC) was performed by using standard protocols. Briefly, IHC was performed on 5-μm sections of formalin-embedded tissue specimens. They were deparaffinized in histolemon (Carlo Erba Reagenti, Rodano, Italy) and rehydrated in graded alcohol. Antigen enhancement was done by incubating the sections in target retrieval solution (DAKO, Copenhagen, Denmark) as recommended. Slides were then transferred to a DAKO autostainer. Staining was done at room temperature as follows: after washes in phosphate buffer, followed by quenching of endogenous peroxidase activity by treatment with 0.1% H2O2, slides were first incubated with blocking serum (DAKO) for 10 min and then with the affinity-purified antibody for 1 hour. After washes, slides were incubated with biotinylated antibody against rabbit Ig for 20 min followed by streptavidin-conjugated peroxidase (DAKO LSABR2 kit). AEC was used as chromogen, according to the supplier’s recommendations for the DAKO LSAB2 kit (Dakocytomation, Glosturp, Denmark). The tissue sections were then counterstained with haematoxylin and coverslipped using Aquatex mounting solution (Merck, Darmstadt, Germany). IHC staining was assessed by two pathologists (OR, LX) and classified into two categories: negative versus positive IHC staining. Each IHC staining was obtained and analyzed twice.

RT-PCR analysis

RT-PCR was used to validate expression data on some of the samples included in the TMA. The primers and PCR

Table 2: Antibodies and antigen retrieval procedures used for IHC

| Protein | Origin | Clone | Dilution | Antigen Retrieval |
|---------|--------|-------|----------|-------------------|
| FGFR1   | SantaCruz | C15    | 1/200    | Demask (DAKO)     |
| MART1   | DAKO   | A103   | 1/2      | Demask (DAKO)     |
| TACC1   | Upstate Biotechn. | 07–229 | 1/500    | Demask (DAKO)     |
| WTI     | Oncogene | WLM04  | 1/100    | Citrate (DAKO)    |
| PSA     | DAKO   | N1517  | rtu*     |                   |

*rtu: ready-to-use solution.
amplification conditions for each tested gene are listed in Tables 3 and 4. Total RNA was extracted from 17 frozen tissue samples obtained from the prostatectomy specimens included in the TMA study. RNA extraction was done by standard protocols [13]. One μg of total RNA was reverse-transcribed at 42°C for 45 min, in a final volume of 20 μl containing: 1× reverse transcriptase buffer (Invitrogen Corp, Carlsbad, CA), 5 mM MgCl₂ (Invitrogen), 1 mM dXTP (Invitrogen), 10 mM dithiothreitol (Invitrogen), 5 μM random hexamers (Roche Diagnostics, Meylan, France), 20 U RNase inhibitor (Promega Biosciences, Madison, WI), 200 U superscript reverse transcriptase (Invitrogen). Reverse transcriptase was inactivated by heating (99°C for 3 min) and cooling (4°C for 5 min). A 4 μl aliquot of this reverse transcription solution was used for PCR using 50 pmol of each specific primer, 10 mM dNTP (Invitrogen), 1.5 mM MgCl₂ (Invitrogen), and 10 × PCR buffer (Invitrogen) in a total volume of 50 μl (see Table 2 for PCR amplification conditions). Next to the last PCR cycle, a final extension reaction was performed (72°C for 7 min). The integrity and amount of RNA available for preparation of all the cDNAs were assessed by amplification of the actin gene. Each PCR reaction included a negative control with H₂O instead of cDNA, a positive control for each cDNA studied (cDNA from PC3 cell line, and LnCaP cell line for WT1 and TACC1 respectively, and a human metastatic melanoma sample for MART1), and a negative control of reverse transcription reaction. The cDNA amplification products were separated by electrophoresis on 1% agarose gel and stained by ethidium bromide staining. The cDNA was then classified as either not amplified (−), or weakly amplified (+), or strongly amplified (++).

Results
Overexpression of FGFR1, MART1, TACC1, and WT1 mRNAs in tumor progression in the LuCaP 23.1 carcinoma model
The respective expression levels of 945 genes in primary, HS, and HR stages of LuCaP 23.1 xenograft prostate carcinoma were compared. They are shown in Figure 1. A gene was considered as differentially expressed when the ratio between its median mRNA level in the primary LuCaP tumor sample and its mRNA level in the HR/HS tumor sample was more than 2-fold. This threshold was defined according to our previous reproducibility experiments [18]. Comparison between primary and HR stages showed that 27 genes were differentially expressed (Table 5). FGFR1, TACC1 and WT1 were overexpressed in HR LuCaP 23.1 carcinoma cells (Figure 1A). Comparison between primary and HS stages showed overexpression of 9 genes (Table 5), including MART1, in HS carcinoma cells (Figure 1B). Although most genes were expressed at the same level in HS and HR stages, FGFR1 was clearly overexpressed in HR stage (Figure 1C).

FGFR1, TACC1 and WT1 proteins display high levels of expression in advanced stages of human prostate carcinoma
We then assessed the expression of four candidate proteins – FGFR1, MART1, TACC1 and WT1 – in human prostate carcinoma samples by IHC. This choice was supported by the availability of a corresponding antibody performing well on paraffin-embedded sections. To this purpose, we constructed a TMA that included 85 prostate carcinoma samples from 85 patients and 11 benign prostate tissue samples issued from 11 of these 85 patients. Results are shown in Table 6 and Figure 2. FGFR1, MART1, and TACC1 IHC staining was cytoplasmic, while WT1 IHC staining was both nuclear and cytoplasmic (Figure 2). Benign prostate tissue expressed FGFR1 and WT1 less frequently than carcinoma samples. Among the 86 tumors, pT3 carcinoma samples expressed FGFR1 and WT1 proteins more frequently than pT2 samples. MART1 was expressed mainly in pT2 carcinomas. MART1 IHC expression was specific to malignant cells. The high expression of FGFR1, WT1 in pT3 tumors and MART1 in pT2 tumors was statistically significant using a chi2 test (Table 6).

Table 3: Primers used for mRNA amplification by RT-PCR.

| Gene   | Forward Primer | Reverse Primer |
|--------|----------------|----------------|
| TACC1  | AAATACGAAGAGACCCGGC | TGTCCAGTTTCTCTTGCG |
| WT1    | ATGAGGATCCCATGGGCCAGCA | CCTGGGACACTGAACGGTCCCCGA |
| MART1  | TGACCCTACAAGATGCCAAG | TCAGCATGTCTCAGGTCT |
| Actin  | AGCAAGAGAGAGGATGCGGAG | CTTGACATGTTCAGAGGGAAGG |

DNA sequences are listed in a 5’→3’ orientation (F and R are the forward and reverse DNA strands, respectively).
MART1, TACC1, and WT1 mRNA levels in human prostate samples correlate with IHC findings

We used RT-PCR to assess whether MART1, TACC1, and WT1 mRNA levels were correlated with IHC expression levels in 2 benign and 16 malignant prostate samples. Because the correlation between FGFR1 transcriptional and post-transcriptional expression has been extensively discussed in the literature (19), we did not assess FGFR1 mRNA levels in our samples. Results are shown in Figure 3.

MART1 mRNA was weakly expressed in only 1/6 pT2 carcinoma, without any expression in pT3 carcinoma or HR (N1 and/or M1) samples (Figure 3). TACC1 mRNA expression was stronger in pT2 and pT3 carcinomas than in benign prostate tissue samples (Figure 3). Furthermore, TACC1 mRNA expression was strong in HR stage carci-

Table 5: 27 and 9 genes differentially expressed between primary and HR, and between primary and HS LuCaP 23.1 xenografts.

| Gene      | Description                                 |
|-----------|---------------------------------------------|
| FGFR1     | Fibroblast growth factor receptor 1         |
| KRT19     | Cytokeratin 19                              |
| CDK4      | Cyclin-dependent kinase 4                   |
| AMFR      | Autocrine motility factor receptor          |
| VEGFR1    | VEGF receptor 1/FLT1                        |
| ITGA3     | Integrin alpha 3/CD49C                      |
| MUC1      | Polymorphic epithelial mucin                |
| GRB7      | GRB7 adaptor                                |
| RELA      | NFKb, p65 subunit                           |
| BCL3      | BCL3 protein                                |
| SRF       | Serum response factor                       |
| MAX       | MAX transcription regulator                 |
| NEO1      | Neogenin homolog 1                          |
| ITGB5     | Integrin beta 5                             |
| RXRA      | Retinoic X receptor alpha                   |
| IGFBP4    | Insulin-like growth factor binding protein  |
| CASP9     | Caspase 9                                   |
| CREBBP    | CREB binding protein                        |
| MMP15     | Membrane-type metalloproteinase 2           |
| SMAD9     | MAD homolog 9                               |
| BAK       | Apoptosis regulator bak                     |
| MMP9      | 92 kDa gelatinase, matrix metalloproteinase-9|
| GATA1     | GATA-binding protein 1                      |
| MRPS      | ATP-binding cassette, sub-family C, member 5|
| PPP2R2C   | PP2A BR gamma                               |
| EPOR      | Erythropoietin receptor                      |
| FZD5      | Frizzled 5, WNT pathway                     |
| MART1     | Melan-a protein                             |
| CSTB      | Cystatin b                                  |
| NR1H3     | Nuclear receptor liver X receptor           |
| VINC      | Vinculin                                    |
| STAM1     | Stathmin, phosphoprotein p19                |
| STAT1     | signal transducer and activator of transcription 1 |
| CBLB      | Cas-Br-M ectropic retroviral transforming sequence b |
| WNT2      | WNT factor 2                                |
| CDH12     | Cadherin 12                                 |

Table 4: PCR conditions for RT-PCR amplification

| Gene | N° of cycles | Denaturation | Annealing | Extension |
|------|--------------|--------------|-----------|-----------|
| WT1  | 35           | 94°C/30 sec  | 64°C/30 sec| 72°C/30 sec|
| MART1| 30           | 94°C/1 min   | 60°C/1 min| 72°C/2 min |
| TACC1| 30           | 94°C/1 min   | 55°C/1 min| 72°C/2 min |
| ACTIN| 25           | 94°C/30 sec  | 55°C/30 sec| 72°C/30 sec|
noma samples (Figure 3). A WT1 mRNA variant (706 bp) was expressed in 2 of 6 pT2 carcinoma samples, while the major WT1 mRNA was strongly expressed in pT3 and HR (N1 and/or M1) carcinoma samples.

Table 6: Expression of FGFR1, MART1, TACC1 and WT1 proteins in human prostate cancer.

| Factors      | benign | pT2 | pT3 | p-value |
|--------------|--------|-----|-----|---------|
|              | No. of patients (%) |        |     |         |
| Age, years   |        |     |     |         |
| <=50         | 0      | 0   | 0   |         |
| >50          | 11     | 39  | 46  |         |
| Gleason      |        |     |     |         |
| 5            | 0      | 3   | 1   | 0.057   |
| 6            | 0      | 7   | 4   |         |
| 7            | 0      | 25  | 28  |         |
| 8            | 0      | 10  |     |         |
| 9            | 0      | 0   | 4   |         |
| FGFR1 status |        |     |     | 0.001   |
| negative     | 9      | 27  | 17  |         |
| positive     | 2      | 12  | 29  |         |
| MART1 status |        |     |     | 0.029   |
| negative     | 11     | 30  | 43  |         |
| positive     | 0      | 9   | 3   |         |
| TACC1 status |        |     |     | 0.756   |
| negative     | 3      | 13  | 12  |         |
| positive     | 8      | 26  | 34  |         |
| WT1 status   |        |     |     | 0.008   |
| negative     | 9      | 24  | 17  |         |
| positive     | 2      | 15  | 29  |         |
Discussion

Using three methods of analysis (DNA microarrays, TMA, and RT-PCR), we have shown that FGFR1, TACC1 and WT1 have much higher levels of expression in human prostate carcinoma than in benign prostate tissue samples, at both mRNA and protein levels. We have also found that FGFR1 and WT1 mRNA are preferentially expressed in pT3 and/or N1/M1 carcinoma samples, and that MART1 expression is correlated with HS stage LuCaP 23.1 carcinoma and pT2 prostate carcinoma. 

High-throughput screening techniques provide opportunities to identify new diagnostic or prognostic markers and innovative therapeutic targets in the whole field of oncology. TMA is a powerful tool to validate DNA microarrays data and extend the scope of gene expression profiling to the post-transcriptional level. Several previous studies [17,20,22,23] have emphasized how TMAs are useful to validate the use of candidate prostate carcinoma markers in routine (IHC) conditions [21].

Potential new markers for prostate cancer progression

We found that expression of FGFR1, WT1, and, to a lesser extent, TACC1 protein is upregulated in advanced stages (pT3 and/or N1/M1) of prostate cancer, whereas MART1 is mainly expressed in localized (pT2) stage prostate cancer. In the same way, we observed that the corresponding mRNAs – FGFR1, TACC1, and WT1 on the one hand, and

Figure 2

Immunohistochemistry of FGFR1, TACC1, WT1, and MART1 protein expression in human prostate tissue samples deposited in tissue microarray. A: FGFR1, MART1, and TACC1 IHC stainings are cytoplasmic, while WT1 staining is both nuclear and cytoplasmic in tumor cells. B: FGFR1, MART1, TACC1, and WT1, expression is more frequent in prostate carcinoma than in benign tissue samples. PSA is used as a positive control, which reacts with prostate secretory and ductal epithelium in normal and neoplastic tissue (demonstration of a neoplasm being of prostatic origin). In the table are indicated the percentages of positive samples with emphasis on a particular stage (in parenthesis).
**MART1** on the other hand – are overexpressed in HR and HS stage LuCaP 23.1 prostate carcinoma, respectively.

**FGFR1** codes for a tyrosine kinase receptor for members of the FGF family of growth factors. It is a potential oncogene, amplified in breast cancers and rearranged in hematopoietic diseases. The case of FGFR1 in prostate cancer is rather clear and our results are in perfect agreement with previous data. Expression of FGFR1 is associated with increased proliferation and aggressive behavior of prostate cancer [24,25].

The **MelanA/MART1** gene encodes a tyrosinase that is a marker of melanocytic differentiation [26]. It can be recognized by cytotoxic T cells [28] and has been considered as a target for immunotherapy [28]. A previous study has shown that the protein is expressed in lymph nodes from breast cancer patients [27]. Our results showed mRNA overexpression in HS stage LuCaP 23.1 model and IHC expression of MART1 in about 20% of prostate carcinomas, mainly pT2 stages. MART1 expression was strictly restricted to carcinoma cells, without any staining in benign prostate tissue. Therefore, we suggest that MART1 expression might be shut down during cancer progression towards hormone resistant and/or advanced clinical stages (T3 and/or N+ and/or M+).

---

**Figure 3**

**RT-PCR assessment of MART1, TACC1, and WT1 mRNA expression in benign and neoplastic human prostate carcinoma samples.** - Lanes 1 and 2: negative control (with H2O instead of cDNA), a positive control for each cDNA studied (cDNA from PC3 cell line and from LNCAP cell line for WT1 and TACC1 respectively, and a human metastatic melanoma sample for MART1). - Lanes 3 and 4: n°1 paired benign and malignant (pT2) tissue samples. - Lanes 5 and 6: n°2 paired benign and malignant (pT2) tissue samples. - Lanes 7–10: distinct pT2 carcinoma samples. - Lanes 11–15: distinct pT3 carcinoma samples (13 and 15 are M+ carcinomas). - Lanes 16–20: distinct HR carcinomas samples. 1st line: WT1 mRNA is detected as a 706 bp PCR product (variant) in 2/6 pT2 carcinoma samples, and as a 851 bp product (wild-type isoform) in 1/2 N1/M1 and 5/5 HR carcinoma samples. No WT1 mRNA is present in benign prostate tissue samples. 2nd line: MART1 mRNA is expressed in only 1/6 pT2 carcinoma sample, but neither in any advanced (pT3 and/or N1/M1) stage nor HR carcinoma samples. 3rd line: TACC1 mRNA is more strongly expressed in both pT2 and pT3 carcinoma than in benign tissue samples. TACC1 mRNA is also expressed in 3/5 HR samples. 4th line: α-actin mRNA amplification is used as a quality control for mRNA extraction and RT-PCR reaction.
TACC1 belongs to the TACC/taxins (Transforming Acidic Coiled-Coil) protein family. Taxins are centrosome and spindle-associated proteins involved in cell division [29]. Mammalian Taxins are probably involved in oncogenesis in different ways [29,30]. TACC1 maps to 8p11, a region that is amplified and rearranged in many malignancies [29-31]. We observed upregulation of TACC1 expression in prostate carcinoma. This is in agreement with previous reports focusing on other tumors [32]. Since we found TACC1 underexpressed in the majority of breast carcinoma [34], TACC1 role remains to be determined. As previously suggested, TACC1 might be involved in multiple complexes that may be deregulated in malignant conditions [33].

The WT1 (Wilms tumor 1) gene encodes a zinc finger transcription factor that modulates the expression of several genes encoding growth factors and receptors (epidermal growth factor receptor [35], insulin-like growth factor II [36], IGF1 receptor [36] and AR [37]. In Wilms tumor, different point mutations have been described in the WT1 locus, suggesting that WT1 altered protein may be directly involved in tumor formation. High WT1 expression levels have been reported in several malignancies [38-41], and have been linked to a poor prognosis [42]. WT1 expression and multidrug resistance are associated in some hematological malignancies, suggesting that WT1 may be a marker for chemoresistance [43]. We found high expression levels of WT1 in pT3 stage carcinoma samples, and expression of wild-type WT1 mRNA in both advanced stages (≥ pT3) and HR stage LuCaP 23.1 carcinomas. These results suggest that WT1 expression in prostate carcinoma may be associated with progression towards hormone resistance and that WT1 may be considered as a
potential hormone resistance and prognostic marker in human prostate carcinoma. These hypotheses are supported by the strong repression of AR promoter by WT1 [44].

Conclusion
In this study, we identified four candidate genes – FGFR1, MART1, TACC1 and WT1 – by gene expression profiling of different stages of prostate carcinoma in an animal model. The clinical relevance of these candidate genes was assessed by IHC on TMA of human prostate carcinoma samples. Our results suggest that each of these four genes may play a role, or at least reflect a stage of prostate carcinoma growth/development/progression. MART1 might be linked to hormone-sensitive growth and localized tumors, whereas FGFR1, TACC1 and WT1 could be associated with hormone-independent growth and advanced prostate carcinoma (see in Figure 4).

Competing interests
The author(s) declare that they have no competing interests.

Authors’ contributions
ED carried out the micro array, tissue array and RT-PCR experiments, designed the study and drafted the manuscript.

FBL, GK, GG and JPD were involved in the acquisition of prostate tumor samples and clinical data.

OR, LX analyzed the immunohistochemistry results.

CN provided home made DNA microarrays.

FBe analyzed gene expression profiling data and helped to draft the manuscript.

DB and LX supervised the study. DB revised the manuscript and gave final approval of the version to be published.

All authors read and approved the final manuscript.

Acknowledgements
We thank F. Birg and D. Maraninchi for encouragements. This work was supported by Institut Paoli-Calmettes and INSERM.

References
1. Parkin DM, Bray Fl, Devesa S: Cancer burden in the year 2000. The global picture. Eur J Cancer 2001, 37(suppl8):S5-S66.
2. Feldman BJ, Feldman D: The development of androgen-independent prostate cancer. Nat Rev Cancer 2001, 1(1):34-45.
3. Isaacs W, Kainu T: Oncogenes and tumor suppressor genes in prostate cancer. Epidemiol Rev 2001, 23(1):36-41.
4. Ostrander EA, Markianos K, Stanford JL: Finding prostate cancer susceptibility genes. Annu Rev Genomics Hum Genet 2004, 5:151-75.
5. Pookpa KP, Visakorpi T: Molecular mechanisms of prostate cancer. Eur Urol 2004, 45(6):683-91.
6. Landers KA, Burger MJ, Tebay MA, Purdie DM, Scells B, Samaranguna H, Lavin MF, Gardiner RA: Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer 2005:950-6.
7. Fromont G, Chene L, Videau M, Vallancien G, Magnin P, Faurnier G, Validire P, Lati A, Cussenet O: Abstract Differential expression of 37 selected genes in hormone-refractory prostate cancer using quantitative tagam real-time RT-PCR. Int J Cancer 2005, 114(2):174-81.
8. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun YX, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AP: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 307(5714):644-8.
9. Ellis WJ, Vessella RL, Buhler KR, Bladou F, True LD, Bigler SA, Curtis D, Lange PH: Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin Cancer Res 1996, 2(6):1039-48.
10. Mousses S, Wagner U, Chen Y, Kim JW, Bubendorf L, Bittner M, Pretlow T, Elkahlioun A, Treipel JB, Kallioniemi OP: Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene 2001, 20(46):6718-23.
11. Van Weerden WM, Romijn JC: Use of nude mouse xenograft models in prostate cancer research. Prostate 2000, 43(4):263-71.
12. Kononen J, Budendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Toholoar J, Mihatsch MJ, Suster J, Kallioniemi OP: Tissue Microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998, 4(7):844-847.
13. Theillet C, Adelaide J, Louasson G, Bonnet-Dorion F, Jacquemier J, Adrime J, Longy M, Katsaros D, Simonetti P, Gaudry P, Birnbaum D: FGFR1 and PLAT genes and DNA amplification at 8q12 in breast and ovarian cancers. Genes Chromosomes Cancer 1993, 7(4):219-226.
14. Bertucci F, Nasser V, Granjeaud S, Eisinger F, Adelaide J, Tagett R, Loriod B, Giacoina A, Benziano A, Devillard E, Jacquemier J, Viens P, Nguyen C, Birnbaum D, Houlgatte R: Gene expression profiles of poor-prognosis primary breast cancer correlate with survival. Hum Mol Genet 2002, 11(8):863-72.
15. Devillard E, Bertucci F, Trempat P, Bouabdallah R, Loriod B, Giacoina A, Brousset P, Granjeaud S, Nguyen C, Birnbaum D, Birg F, Houlgatte R, Xerri L: Gene expression profiling defines molecular subtypes of classical Hodgkin’s disease. Oncogene 2002, 21(19):3095-3102.
16. Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998, 95(25):14863-14868.
17. Richter J, Wagner U, Kononen J, Fijan A, Bruderer J, Schmid U, Ackermann D, Maurer R, Alund G, Knönagel H, Rist M, Wilker K, Anabitarte M, Hering F, Hardmeier T, Schönberger A, Flury R, Jager P, Fehr J, Schrami P, Moch H, Mihatsch MJ, Gasser T, Kallioniemi OP, Sauter G: High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol 2000, 157(3):787-794.
18. Bertucci F, Van Hulst S, Bernard K, Loriod B, Granjeaud S, Tagett R, Starkey M, Nguyen C, Jordan B, Birnbaum D: Expression scanning of an array of growth control genes in human tumor cell lines. Oncogene 1999, 18(26):3905-3912.
19. Edwards J, Krishna NS, Witton CJ, Bartlett M: Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res 2003, 9(14):5271-81.
20. Jacquemier J, Ginestier C, Rougemont J, Bardou V, Charafe-Jauffret E, Geneix J, Adelaide J, Koki A, Houvenaeghel G, Hassoun J, Maraninchi D, Viens P, Birnbaum D, Bertucci F: Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 2005, 65(3):767-79.
21. Varambally S, Yu J, Lazarin B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Bechic MJ, Wei JT, Pienta KJ, Ghoish D, Rubin MA, Chinnaiyan AP: Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005, 8(3):393-406.
22. Amler LC, Agus DB, LeDuc C, Sapinossio ML, Fox WD, Kern S, Lee D, Wang V, Leyrens M, Higgins B, Martin J, Gerald W, Dracopoli N, Cor- don-Cardo C, Scher HI, Hampton GM. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res 2000, 60(21):6134-4.

23. Mousses S, Bubendorf L, Wagner U, Hostetter G, Kononen J, Cor- nelisson K, Goldberger N, Elkahlon AG, Willi N, Kaivisto P, Fehlre W, Raffeld M, Sauder G, Kallioniemi OP. Clinical validation of can- didate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. Cancer Res 2002, 62(5):1256-60.

24. Feng S, Wang F, Matsubara A, Kan M, McKeenan WL: Fibroblast growth factor receptor 2 limits and receptor 1 accelerates-tumorigenicity of prostate epithelial cells. Cancer Res 57(23):3569-78. 1997 Dec.

25. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA. Expression of bFGF/FGFR-I and vascular proliferation related to clinico-pathologic features and tumor progression in localized prostate cancer. Vochows Arch 2006, 448(1):68-74. Epub 2005 Oct 12.

26. Busam KJ, Chen YT, Old LJ, Stockert E, Iversen K, Coplan KA, Rosai J, Barnhill RL, Jungbluth AA. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am J Surg Pathol 1998, 22(8):756-72.

27. Yan S, Brennick JB. Falsenpositive rate of the immunoperoxixi- dase stains for MART1/MelanA in lymph node. Am J Surg Pathol 2004, 28(5):596-600.

28. Rivoltini L, Squarizani P, Luftois DJ, Castelli C, Tarzini P, Mazzocchi A, Rini F, Viggiano V, Belli F, Parmiani G: A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy. Cancer Res 1999, 59(23):6019-24.

29. Gergely F, Kidd D, Jeffers K, Wakefield JG, Raff JW: D-TACC: a novel centrosomal protein required for normal spindle function in the early Drosophila embryo. EMBO J 2000, 19(2):241-52.

30. Still IH, Hamilton M, Vince P, Wolfman A, Cowell J: Cloning of TACCI, an embryonically expressed, potentially transforming coiled coil containing gene from the 8p11 breast cancer amplicon. Oncogene 1999, 18(27):6528-8.

31. Still IH, Vincent P, Cowell JK. The third member of the transforming acidic coiled coil-containing gene family, TACC3, maps in 4p16, close to translocation breakpoints in multiple mye- loma, and is upregulated in various cancer cell lines. Genomics 1999, 58(2):165-70.

32. Chen HM, Schmeichel KL, Mian IS, Leliweer S, Petersen OW, Bissell MJ: AZU-1: a candidate breast tumor suppressor and biomar- ker for tumor progression. Mol Biol Cell 2000, 11(4):1357-67.

33. Ugolini F, Adelaide J, Charafe-Jauffret E, Nguyen C, Jacquemier J, Bissell MJ. Differential expression assay of chromosome arm 8p genes identifies Frizzled-related (FRP1/FRZB) and Fibroblast Growth Factor Receptor 1 (FGFR1) as candidate breast cancer genes. Oncogene 1999, 18(10):1903-10.

34. Conte N, Charaf-Jauffret E, Delval B, Adelaide J, Ginestier C, Genest J, Isordon D, Jacquemier J, Birnbaum D: Carcinogenesis and translational controls: TACC1 is down-regulated in human cancers and associates with mRNA regulators. Oncogene 2000, 21(36):5619-30.

35. Wang ZY, Qiu QQ, Enge KT, Deuel TF. A second transcriptionally active DNA-binding site for the Wilms tumor gene product, WT1. Proc Natl Acad Sci 1993, 90(19):8896-900.

36. Werner H, Roberts CT, Rauscher FJ 3rd, LeRoith D: Regulation of insulin-like growth factor 1 receptor gene expression by the Wilms’ tumor suppressor WT1. J Mol Neurosci 1996, 7(2):111-23.

37. Shimamura R, Fraizer GC, Trapman J, Lau YC, Saunders GF: The Wilms’ tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, Mullerian-inhibiting substance, and the androgen receptor. Clin Cancer Res 1997, 3(12):2571-80.

38. Tamaki H, Ogawa H, Ohyashiki K, Ohyashiki JH, Iwama H, Inoue K, Soma T, Oka Y, Tatekawa T, Oji Y, Tsuibo A, Kim EH, Kawakami M, Fuchigami K, Tomonaga M, Toyama K, Aozasa K, Kishimoto T, Sugi- yama H: The Wilms’ tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syn- dromes. Leukemia 1999, 13(3):393-9.

39. Trka J, Kalinova M, Hrusak O, Zuna J, Krejci O, Madzko J, Sediacek P, Vavra V, Michalova K, Jarosova M, Stary J: Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia 2002, 16(7):1381-9.

40. Rodeck U, Bossler A, Kari C, Humphreys CW, Gyori T, Maurer J, Thiel E, Menssen HD: Expression of the wt1 Wilms’ tumor gene by normal and malignant human melanocytes. Int J Cancer 1994, 59(1):78-82.

41. Viel A, Giannini F, Capozzi E, Canzonieri V, Scarabelli C, Gloghini A, Boiocchi M: Molecular mechanisms possibly affecting WT1 function in human ovarian tumors. Int J Cancer 1994, 57(4):515-21.

42. Bergmann L, Mietheing A, Maurer U, Brierje J, Karakas T, Weidmann E, Hoepler D: High levels of Wilms’ tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long- term outcome. Blood 1997, 90(3):1217-25.

43. Hirose M: The role of Wilms’ tumor genes. J Med Invest 1999, 46(3–4):130-140.

44. Zaia A, Fraizer GC, Plantanelli L, Saunders GF: Transcriptional reg- ulation of the androgen signaling pathway by the Wilms’ tumor suppressor gene WT1. Anticancer Res 21(1A):1-10.

Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/6/272/pre-pub